UPDATE: Ascendiant Capital Markets Upgrades Solta Medical to Strong Buy

Ascendiant Capital Markets raised its rating on Solta Medical SLTM from Buy to Strong Buy with a $3.75 price target. Ascendiant Capital Markets commented, "Revenue was $35.0 MM (+28%), compared to the consensus estimate of $33.9 MM, in what is seasonally the slowest quarter of the year. GAAP EPS was ($0.04) compared to consensus EPS of ($0.03). Non-GAAP adjusted EPS was $0.03. … In our opinion, the recent weakness in the stock has created an attractive entry point. Hence, we are upgrading our rating to Strong Buy. Our 12-month price target of $3.75 represents a target forward EV/EBITDAS multiple of 12.3x our 2013 estimate." Solta Medical closed at $2.69 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPrice TargetIntraday UpdateAnalyst RatingsAscendiant Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!